Your browser doesn't support javascript.
loading
Treatment during a developmental window prevents NF1-associated optic pathway gliomas by targeting Erk-dependent migrating glial progenitors.
Jecrois, Emmanuelle S; Zheng, Wang; Bornhorst, Miriam; Li, Yinghua; Treisman, Daniel M; Muguyo, Daphine; Huynh, Sharon; Andrew, Shayne F; Wang, Yuan; Jiang, Jingwen; Pierce, Brianna R; Mao, Hongmei; Krause, Matthew K; Friend, Austin; Nadal-Nicolas, Francisco; Stasheff, Steven F; Li, Wei; Zong, Hui; Packer, Roger J; Zhu, Yuan.
Afiliação
  • Jecrois ES; Gilbert Family Neurofibromatosis Institute, Children's National Hospital, Washington, DC 20010, USA; Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC 20010, USA; Center for Neuroscience Research, Children's National Hospital, Washington, DC 20010, USA; Neurosci
  • Zheng W; Gilbert Family Neurofibromatosis Institute, Children's National Hospital, Washington, DC 20010, USA; Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC 20010, USA; Center for Neuroscience Research, Children's National Hospital, Washington, DC 20010, USA.
  • Bornhorst M; Gilbert Family Neurofibromatosis Institute, Children's National Hospital, Washington, DC 20010, USA; Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC 20010, USA; Center for Neuroscience Research, Children's National Hospital, Washington, DC 20010, USA; Center f
  • Li Y; Gilbert Family Neurofibromatosis Institute, Children's National Hospital, Washington, DC 20010, USA; Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC 20010, USA; Center for Neuroscience Research, Children's National Hospital, Washington, DC 20010, USA.
  • Treisman DM; Gilbert Family Neurofibromatosis Institute, Children's National Hospital, Washington, DC 20010, USA; Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC 20010, USA; Center for Neuroscience Research, Children's National Hospital, Washington, DC 20010, USA.
  • Muguyo D; Gilbert Family Neurofibromatosis Institute, Children's National Hospital, Washington, DC 20010, USA; Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC 20010, USA; Center for Neuroscience Research, Children's National Hospital, Washington, DC 20010, USA.
  • Huynh S; Gilbert Family Neurofibromatosis Institute, Children's National Hospital, Washington, DC 20010, USA; Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC 20010, USA; Center for Neuroscience Research, Children's National Hospital, Washington, DC 20010, USA.
  • Andrew SF; Gilbert Family Neurofibromatosis Institute, Children's National Hospital, Washington, DC 20010, USA; Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC 20010, USA; Center for Neuroscience Research, Children's National Hospital, Washington, DC 20010, USA.
  • Wang Y; Gilbert Family Neurofibromatosis Institute, Children's National Hospital, Washington, DC 20010, USA; Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC 20010, USA; Center for Neuroscience Research, Children's National Hospital, Washington, DC 20010, USA.
  • Jiang J; Gilbert Family Neurofibromatosis Institute, Children's National Hospital, Washington, DC 20010, USA; Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC 20010, USA; Center for Neuroscience Research, Children's National Hospital, Washington, DC 20010, USA.
  • Pierce BR; Gilbert Family Neurofibromatosis Institute, Children's National Hospital, Washington, DC 20010, USA; Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC 20010, USA; Center for Neuroscience Research, Children's National Hospital, Washington, DC 20010, USA.
  • Mao H; Gilbert Family Neurofibromatosis Institute, Children's National Hospital, Washington, DC 20010, USA; Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC 20010, USA; Center for Neuroscience Research, Children's National Hospital, Washington, DC 20010, USA.
  • Krause MK; Gilbert Family Neurofibromatosis Institute, Children's National Hospital, Washington, DC 20010, USA; Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC 20010, USA; Center for Neuroscience Research, Children's National Hospital, Washington, DC 20010, USA.
  • Friend A; Gilbert Family Neurofibromatosis Institute, Children's National Hospital, Washington, DC 20010, USA; Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC 20010, USA; Center for Neuroscience Research, Children's National Hospital, Washington, DC 20010, USA.
  • Nadal-Nicolas F; Retinal Neurophysiology Section, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Stasheff SF; Gilbert Family Neurofibromatosis Institute, Children's National Hospital, Washington, DC 20010, USA; Retinal Neurophysiology Section, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Li W; Retinal Neurophysiology Section, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Zong H; Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA 22908, USA.
  • Packer RJ; Gilbert Family Neurofibromatosis Institute, Children's National Hospital, Washington, DC 20010, USA.
  • Zhu Y; Gilbert Family Neurofibromatosis Institute, Children's National Hospital, Washington, DC 20010, USA; Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC 20010, USA; Center for Neuroscience Research, Children's National Hospital, Washington, DC 20010, USA; Neurosci
Dev Cell ; 56(20): 2871-2885.e6, 2021 10 25.
Article em En | MEDLINE | ID: mdl-34428430
The mechanism of vulnerability to pediatric low-grade gliomas (pLGGs)-the most common brain tumor in children-during development remains largely unknown. Using mouse models of neurofibromatosis type 1 (NF1)-associated pLGGs in the optic pathway (NF1-OPG), we demonstrate that NF1-OPG arose from the vulnerability to the dependency of Mek-Erk/MAPK signaling during gliogenesis of one of the two developmentally transient precursor populations in the optic nerve, brain-derived migrating glial progenitors (GPs), but not local progenitors. Hyperactive Erk/MAPK signaling by Nf1 loss overproduced GPs by disrupting the balance between stem-cell maintenance and gliogenesis of hypothalamic ventricular zone radial glia (RG). Persistence of RG-like GPs initiated NF1-OPG, causing Bax-dependent apoptosis in retinal ganglion cells. Removal of three Mek1/Mek2 alleles or transient post-natal treatment with a low-dose MEK inhibitor normalized differentiation of Nf1-/- RG-like GPs, preventing NF1-OPG formation and neuronal degeneration. We provide the proof-of-concept evidence for preventing pLGGs before tumor-associated neurological damage enters an irreversible phase.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células-Tronco / Neurofibromatose 1 / Glioma do Nervo Óptico / Sistema de Sinalização das MAP Quinases Tipo de estudo: Risk_factors_studies Limite: Animals Idioma: En Revista: Dev Cell Assunto da revista: EMBRIOLOGIA Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células-Tronco / Neurofibromatose 1 / Glioma do Nervo Óptico / Sistema de Sinalização das MAP Quinases Tipo de estudo: Risk_factors_studies Limite: Animals Idioma: En Revista: Dev Cell Assunto da revista: EMBRIOLOGIA Ano de publicação: 2021 Tipo de documento: Article